多周期粒细胞集落刺激因子可提高失代偿期肝硬化患者生存时间:一项随机试验
该开放标签随机试验纳入100例无慢加急性肝衰竭的失代偿期肝硬化患者,比较每3个月给予5天G-CSF共4周期联合标准治疗与单用标准治疗的疗效。结果显示G-CSF组12个月生存率显著高于对照组,且CD34+细胞增多、CTP和MELD评分降低、腹水控制改善等,G-CSF安全耐受。
要点
- 多周期G-CSF联合标准治疗可显著提高失代偿期肝硬化患者12个月生存率。
- G-CSF组CD34+细胞显著增加,CTP和MELD评分降低,感染和住院减少。
- G-CSF可能作为失代偿期肝硬化患者等待肝移植的桥接治疗。
核心结论
- 多周期G-CSF可增加失代偿期肝硬化患者造血干细胞数量并提高接受标准治疗患者的生存率。
研究设计与样本
- 开放标签随机试验,纳入100例无慢加急性肝衰竭的失代偿期肝硬化患者,来自单中心,2016年7月至2018年6月。
- 患者随机分为G-CSF组(每3个月给予5天G-CSF共4周期联合标准治疗,n=50)或单用标准治疗组(n=50)。
主要发现
- 治疗开始后12个月生存率G-CSF组为74%,对照组为42%(P < .001)。
- G-CSF组第6天CD34+细胞较第0天显著增加(P < .001),对照组无显著变化。
- 与对照组相比,G-CSF组CTP和MELD评分显著降低、腹水控制改善、感染和住院减少、肝硬度降低、生活质量提高、符合肝移植标准者减少(P < .05)。
- 两组营养均较基线无改善;G-CSF安全且耐受良好。
临床怎么用
- 对于无慢加急性肝衰竭的失代偿期肝硬化患者,可考虑在标准治疗基础上加用多周期G-CSF以改善生存。
- G-CSF可能作为失代偿期肝硬化患者等待肝移植的桥接治疗。
局限性
- 开放标签设计,非盲法。
- 单中心研究,样本量100例。
- 未报告对慢加急性肝衰竭患者的效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: There is controversy regarding the inclusion of granulocyte colony stimulating factor (G-CSF) in the treatment of decompensated cirrhosis. Previous studies tested only a single cycle of G-CSF administration or were underpowered to detect changes in survival time. We performed an adequately powered study to determine whether multiple cycles of G-CSF increased the survival of patients 1 year after the start of therapy. METHODS: We conducted an open-label trial of 100 patients with decompensated cirrhosis without acute-on-chronic liver failure at a tertiary center from July 2016 through June 2018. The patients were assigned randomly to a group given 5 days of G-CSF every 3 months, with standard medical therapy, in 4 cycles (group A, n = 50), or standard medical therapy alone (group B, n = 50). The primary outcome was survival for 12 months after treatment began. Secondary outcomes were an increase in the number of CD34+ cells at day 6 compared with day 0, along with reductions in Child-Turcotte-Pugh and model for end-stage liver disease scores, increased control of ascites, reduced decompensation and episodes of infection, fewer hospitalizations, lower liver stiffness measurements, increased quality of life and nutrition, fulfilment of liver transplant criteria, and fewer adverse events at 12 months after the start of treatment. RESULTS: Groups A and B were comparable at baseline. Survival at 12 months after initiation of treatment was significantly higher in group A (74%) than in group B (42%) (P < .001). Blood samples from patients in group A had significantly more CD34+ cells on day 6 than on day 0 (P < .001); there was no significant change in group B. Compared with patients in group B, patients in group A had significant reductions in Child-Turcotte-Pugh and model for end-stage liver disease scores, increased ascites control, fewer infections and hospitalizations, lower liver stiffness measurements, an increased quality of life, and a lower number fulfilled the liver transplant criteria (P < .05). There was no improvement in nutrition in either group compared with baseline. G-CSF was safe and well tolerated. CONCLUSIONS: Administration of multiple cycles of G-CSF increases the numbers of hematopoietic stem cells and survival of patients with decompensated cirrhosis receiving standard medical treatment. The addition of G-CSF to medical treatment might provide a bridge to liver transplantation for these patients. ClincialTrials.gov no: NCT03415698.
引用
- De A, Kumari S, Singh A, et al. Multiple Cycles of Granulocyte Colony-Stimulating Factor Increase Survival Times of Patients With Decompensated Cirrhosis in a Randomized Trial. Clin Gastroenterol Hepatol. 2020. PMID: 32088302. doi:10.1016/j.cgh.2020.02.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。